Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Achieve Life Sciences, Inc. (ACHV)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
5.33-0.05 (-0.93%)
At close: 04:00PM EST
5.24 -0.09 (-1.69%)
After hours: 04:13PM EST
Advertisement
Full screen
Loading interactive chart...
  • GlobeNewswire

    Achieve Life Sciences Announces Last Subject Dosed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette Cessation

    Topline Data Expected in 2Q 2023SEATTLE, Wash and VANCOUVER, British Columbia, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the final subject of the Company’s Phase 2 ORCA-V1 trial has completed treatment in the study. ORCA-V1 is evaluating the efficacy and safety of cytisiniclin

  • GlobeNewswire

    Achieve Life Sciences to Participate at the 2023 SVB Securities Global Biopharma Conference

    SEATTLE, Wash and VANCOUVER, British Columbia, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will participate in one-on-one meetings during the 2023 SVB Securities Global Biopharma Conference. The conference is taking place virtually from February 14-16, 2023.To arrange one-on-one m

  • GlobeNewswire

    Achieve Life Sciences Announces Granting of New Hire Inducement Award

    SEATTLE, Wash and VANCOUVER, British Columbia, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the Company has issued an inducement grant of stock options to a new employee. Achieve’s Board of Directors approved the new employment inducement grant to purchase 15,000 shares of Achieve’s commo

Advertisement
Advertisement